Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 15/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1829222 | 0.81 | SIRT2 (0.47) | SIRT2KCNN4 | |
| SCHEMBL7789115 | 0.80 | SIRT2 (0.42) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL7789120 | 0.80 | SIRT2 (0.42) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL1040045 | 0.79 | CYP11B1 (0.41) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL8447651 | 0.79 | SIRT2 (0.51) | SIRT2CYP11B1CYP11B2 | |
| SCHEMBL5682164 | 0.78 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL670904 | 0.78 | CYP11B1 (0.43) | SIRT2CYP11B1CYP11B2ENPP2 | |
| SCHEMBL8499551 | 0.76 | SIRT2 (0.42) | SIRT2CYP11B1CYP11B2KCNN4ENPP2 | |
| SCHEMBL693097 | 0.76 | CYP11B1 (0.41) | SIRT2CYP11B1CYP11B2KCNN4TRPM8 | |
| SCHEMBL28422181 | 0.76 | ADA (0.47) | SIRT2CYP11B1CYP11B2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | claimed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | claimed |
| CN-108314654-B | Intermediate for preparing medetomidine and preparation method and application thereof | 山东百诺医药股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-9540331-B2 | Preparation method of dexmedetomidine intermediate | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2017-01-10 | — | — | US | disclosed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | TIANJIN WEIJIE PHARMACEUTICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
| EP-1681290-B9 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2013-06-19 | — | — | EP | disclosed |
| EP-1681290-B1 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL (JP) | 2011-11-16 | — | — | EP | disclosed |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2011-10-27 | — | — | US | disclosed |
| US-7141598-B2 | Imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY, LTD. (JP) | 2006-11-28 | — | — | US | disclosed |
| EP-1681290-A2 | Imidazole derivatives, production method thereof and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2006-07-19 | — | — | EP | disclosed |
| EP-1334106-B1 | IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2006-05-24 | — | — | EP | disclosed |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1334106-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002040484-A2 | NOVEL IMIDAZOLE DERIVATIVES, PRODUCTION METHOD THEREOF AND USE THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272594-A1 | PREPARATION METHOD OF DEXMEDETOMIDINE INTERMEDIATE | AVPR2, TET1, TET2 | SIRT2 1503/4885MLYCD 1695/4885CYP11B1 34/4885 |
| US-20040033935-A1 | Novel imidazole derivatives, production method thereof and use thereof | CYP17A1, CYP21A2, CYP19A1 | SIRT2 2146/4885MLYCD 2783/4885CYP11B1 12/4885 |
| US-20110263595-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | FLT3, NTRK1, PRKDC | SIRT2 4191/4885MLYCD 1830/4885CYP11B1 2481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.